ProtoKinetix 10-K: Going Concern, Material Weaknesses, and $393K Loss
PKTX has more than doubled off its 52-week low of $0 on light trading volume (0.1× avg).
Summary
ProtoKinetix's FY2025 10-K reveals a going concern warning, material weaknesses in financial controls, and a $393,650 net loss with only $1,118 in cash remaining.
Key Events · Earnings and Guidance · PKTX
-
Going Concern Qualification
Auditor Davidson & Company LLP issued a going concern opinion citing a $48.6 million accumulated deficit, $183,266 working capital deficiency, and no commercially viable product.
-
Material Weaknesses in Internal Controls
Management disclosed insufficient segregation of duties and inadequate corporate governance documentation, concluding ICFR was not effective as of December 31, 2025.
-
Cash Position Critical
Only $1,118 in cash at year-end 2025, with negative working capital of $183,266. The company states it does not have sufficient capital to meet short-term cash flow projections.
-
Massive Dilution Overhang
94,790,000 stock options (weighted average exercise price $0.028) and 23,700,000 warrants outstanding, versus 411.6 million shares outstanding as of September 3, 2026.
Analysis · PKTX · Life Sciences
The auditor's going concern qualification and management's admission of material weaknesses in internal controls are critical red flags for a company with only $1,118 in cash and a $183,266 working capital deficit. The company has no revenue, a $48.6 million accumulated deficit, and is dependent on selling common stock at $0.01 per share to fund operations. The stock trades at $0.0002, making further dilution extremely costly for existing holders. The filing also reveals 94.79 million options and 23.7 million warrants outstanding, creating massive potential overhang. This is a survival situation, not a routine annual report.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PKTX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $78.3K. The 52-week trading range was $0.00 to $0.01. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.